BioAmber Inc (BIOA) said that the Toronto Stock Exchange (TSX) has notified the company that it is reviewing, on an expedited basis, the company's eligibility for continued listing.
This review results from the company not being in a position to obtain the approval of the TSX in connection with its registered direct offering.
BioAmber was notified of the listing review on 12 February 2018. A meeting with the continued listing committee of the TSX is scheduled to be held on 15 February 2018, at which the company may make submissions. Since the suspension of trading and delisting of the company's shares from the TSX is a possible outcome, the company may seek alternative Canadian marketplaces on which to be listed, including the TSX Venture Exchange.
BioAmber Inc (BIOA) said that the Toronto Stock Exchange (TSX) has notified the company that it is reviewing, on an expedited basis, the company's eligibility for continued listing.
This review results from the company not being in a position to obtain the approval of the TSX in connection with its registered direct offering.
BioAmber was notified of the listing review on 12 February 2018. A meeting with the continued listing committee of the TSX is scheduled to be held on 15 February 2018, at which the company may make submissions. Since the suspension of trading and delisting of the company's shares from the TSX is a possible outcome, the company may seek alternative Canadian marketplaces on which to be listed, including the TSX Venture Exchange.
No comments:
Post a Comment